摘要目的 比较康柏西普(Conbercept)与雷珠单抗(Ranibizumab)联合小梁切除术治疗新生血管性青光眼(NVG)的临床效果.方法 选取2014年6月至2015年5月收治的NVG 68例(68眼),随机分为康柏西普组和雷珠单抗组,每组34例(34眼).两组分别行玻璃体内注射康柏西普或雷珠单抗,均待虹膜新生血管消退及眼压稳定后行小梁切除术,并尽可能早地行广泛视网膜光凝术,术后门诊随访7~12个月.结果 两组随访末期眼压控制的成功率、新生血管复发率、视力及并发症发生率的差异均无统计学意义(P>0.05);虹膜及前房角新生血管消退时间,康柏西普组为(3.22±0.74)d短于雷珠单抗组的(3.84±0.85)d,差异有统计学意义(P<0.05);两组术后眼压均低于术前(P<0.05),术后不同时间点的眼压两组之间的差异均无统计学意义(P>0.05).结论 玻璃体内注射康柏西普或雷珠单抗联合小梁切除术治疗NVG,均可使虹膜与前房角新生血管消退,控制眼压,改善视力,但玻璃体内注射康柏西普在缩短新生血管消退时间上更具优势.

abstractsObjective To compare the clinical efficacy of Conbercept and Ranibizumab combined with trabeculectomy for the treatment of neovascular glaucoma (NVG).Methods Sixty-eight eyes of 68 patients with NVG from June 2014 to May 2015 were randomly divided into Conbercept group and Ranibizumab group.Each group contained 34 eyes of 34 cases.The two groups respectively received intravitreal injection of Conbercept or Ranibizumab.All the patients underwent trabeculectomy after iris new vessels disappeared and the intraocular pressure was stable.The panretinal photocoagulation was performed as early as possible.After operation, the patients were followed up for 7-12 months.Results There was no significant difference in successful rate of intraocular pressure control, recurrence rate of iris or chamber angle neovascularization,visual acuity or the incidence of complication between the two groups at the end of follow-up (P>0.05).The extinction time of iris and chamber angle neovascularization in Conbercept group (3.22±0.74)d was shorter than that in ranibizumab group (3.84±0.85)d (P<0.05).After operation, the intraocular pressure of both groups were lower than those before operation (P<0.05), but there was no significant difference between the two groups at different time points (P>0.05).Conclusion Intravitreal injection of Conbercept or Ranibizumab, combined with trabeculectomy in treating NVG all can promote extinction of neovascularization of iris and chamber angle , control intraocular pressure, and improve visual acuity.But intravitreal injection of Conbercept has the advantage in shortening the extinction time of neovascularization.